Costs for implantable hearing aids are covered by health insurance companies
At the Department of Otorhinolaryngology and the German Hearing Center (Deutsches HörZentrum Hannover, DHZ) of the Hannover Medical School (Medizinische Hochschule Hannover, MHH), anyone can receive a fully or partially implantable hearing system as part of an agreement between MHH and health insurance companies if medical necessity is established. This covers not only cochlear implants but also BAHA, MET, RetroX, Vibrant Soundbridge and Carina devices, as well as the midbrain and brainstem implants AMI and ABI.
Over the past years, the Department of Otorhinolaryngology and the DHZ have provided substantiated evidence for their internationally leading expertise and their substantial experience with cochlear implants – both in patient care and research. They have also extended the clinical application and scientific development of conventional and partially implantable hearing systems. Clinical practice is stable and successful, as demonstrated by the continuously increasing number of patients. This is why all health insurance providers have shown their trust and confidence in us for a number of years by guaranteeing, subject to medical necessity and if sufficient budget capacity is available, that every patient will receive an implantable hearing system without the requirement for a case-by-case assessment. Medical necessity is always established by providing complete audiological diagnostics.
We would like to stress that stable structures were established many years ago to provide implantable hearing systems generally to all patients who have statutory health care insurance. This means that all patients concerned will receive sustainable health care under their insurance.
Special emphasis is placed on the surgical technique which was developed in Hannover and which enables us to preserve a patient’s hearing (not only by means of cochlear implantation). The ENT team led by Professor Thomas Lenarz has also developed novel surgical systems and medical products that are ‘world-firsts’ and which allow even combined severe auditory diseases to be treated efficiently and sufficiently. For a university-based ENT department to have this kind of strategic focus is unparalleled in Germany.